Drug Profile
Research programme: toll-like receptor antagonist - Janus Biotherapeutics/Roche
Alternative Names: JB6121; TLR inhibitor - Janus Biotherapeutics/Roche; Toll-like receptor inhibitor - Janus Biotherapeutics/RocheLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Janus Biotherapeutics
- Developer Janus Biotherapeutics; Roche
- Class Small molecules
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Systemic lupus erythematosus
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA (PO)
- 20 Aug 2015 Janus Biotherapeutics and Roche agree to co-develop TLR Antagonist in USA for Autoimmune Disorders